Publications by authors named "Mark Carmichael"

Claim this Profile
S
Systemic Mastocytosis: The Difficult Patient with a Rare Disease. Case Presentation and Brief Review.
Daniel H Desmond, Mark G Carmichael

Hawaii J Med Public Health· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next-Generation Gene Sequencing Differentiates Hypoplastic Myelodysplastic Syndrome from Aplastic Anemia.
Jeffrey L Lew, Joshua L Fenderson, Mark G Carmichael

Hawaii J Med Public Health· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atypical Histiocyte-Rich Sweet's Syndrome.
Sharon Chi, Marcia Leung, Mark Carmichael, Michael Royer, Sunghun Cho

Case Rep Dermatol Med· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent Systemic Chemoimmunotherapy and Sofosbuvir-Based Antiviral Treatment in a Hepatitis C Virus-Infected Patient With Diffuse Large B-Cell Lymphoma.
Evan C Ewers, Phalgoon A Shah, Mark G Carmichael, Tomas M Ferguson

Open Forum Infect Dis· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis of atypical hemolytic uremic syndrome and response to eculizumab therapy.
May H Nguyen, Jacob J Mathew, Troy M Denunzio, Mark G Carmichael

Hawaii J Med Public Health· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AE37: a novel T-cell-eliciting vaccine for breast cancer.
Alan K Sears, Sonia A Perez, Guy T Clifton, Linda C Benavides, Jeremy D Gates, Mark G Carmichael

Expert Opin Biol Ther· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.
Linda C Benavides, Alan K Sears, Jeremy D Gates, Guy T Clifton, Kevin S Clive, Mark G Carmichael

Expert Rev Vaccines· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide.
Jeremy D Gates, Guy T Clifton, Linda C Benavides, Alan K Sears, Mark G Carmichael

Vaccine· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.
Ritesh Patil, Guy T Clifton, Jarrod P Holmes, Asna Amin, Mark G Carmichael

J Am Coll Surg· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04.
Mark G Carmichael, Linda C Benavides, Jarrod P Holmes, Jeremy D Gates, Elizabeth A Mittendorf

Cancer· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Linda C Benavides, Jeremy D Gates, Mark G Carmichael, Ritesh Patil, Jarrod P Holmes

Clin Cancer Res· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.
Jeremy D Gates, Mark G Carmichael, Linda C Benavides, Jarrod P Holmes, Matthew T Hueman

J Am Coll Surg· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Asna Amin, Linda C Benavides, Jarrod P Holmes, Jeremy D Gates, Mark G Carmichael

Cancer Immunol Immunother· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Jarrod P Holmes, Jeremy D Gates, Linda C Benavides, Matthew T Hueman, Mark G Carmichael

Cancer· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
Jarrod P Holmes, Linda C Benavides, Jeremy D Gates, Mark G Carmichael, Matthew T Hueman

J Clin Oncol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metastatic malignant teratoma arising from mediastinal nonseminomatous germ cell tumor: a case report.
Jacob Collen, Mark Carmichael, Tanya Wroblewski

Mil Med· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central nervous system anaplastic large cell lymphoma in an adult: successful treatment with a combination of radiation and chemotherapy.
Mark G Carmichael

Mil Med· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The demonstration of pulmonary neuroendocrine cell hyperplasia with tumorlets in a patient with chronic cough and a history of multiple medical problems.
Mark G Carmichael, Lisa L Zacher

Mil Med· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 59-year-old woman with tuberculous meningitis masked by hepatic encephalopathy.
Mark G Carmichael, Jennifer C Thompson, Thomas B Buttolph, Jeffrey A Hooke

Mil Med· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis